CTLA4 and hepatocellular carcinoma: A neoadjuvant randomized trial treated nine early-stage HCC patients with nivolumab (ICI, anti-PD-1 antibody) 3 mg on the first day of a 14-day cycle, plus ipilimumab (ICI, anti-CTLA-4 antibody) 1 mg/kg on the first day of every 1.5 months for 2 years [69].